摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-cyclopropyl-2-(diethoxymethyl)-5,6-dimethylpyrimidine | 1215358-38-5

中文名称
——
中文别名
——
英文名称
4-cyclopropyl-2-(diethoxymethyl)-5,6-dimethylpyrimidine
英文别名
——
4-cyclopropyl-2-(diethoxymethyl)-5,6-dimethylpyrimidine化学式
CAS
1215358-38-5
化学式
C14H22N2O2
mdl
——
分子量
250.341
InChiKey
QMCCFNSRLYZFEY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    18
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.71
  • 拓扑面积:
    44.2
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    4-chloro-2-(diethoxymethyl)-5,6-dimethylpyrimidine 、 环丙基溴化镁 在 iron(III)-acetylacetonate 作用下, 以 四氢呋喃N-甲基吡咯烷酮 为溶剂, 反应 0.08h, 以89%的产率得到4-cyclopropyl-2-(diethoxymethyl)-5,6-dimethylpyrimidine
    参考文献:
    名称:
    [EN] AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE
    [FR] COMPOSÉS CYCLIQUES AROMATIQUES AZOTÉS À 6 CHAÎNONS ET LEUR UTILISATION
    摘要:
    本发明提供了具有出色的PDE10抑制活性的芳香氮含6元环化合物。本发明涉及以下式[I0]所代表的芳香氮含6元环化合物或其药学上可接受的盐,其制备方法,以及将所述化合物用作PDE10抑制剂,以及包含所述化合物作为活性成分的药物组合物:式[I0]其中:X1、X2和X3各自独立地为N或CH,并且至少两个X1、X2和X3为N;A为*-CH=CH-,*-C(Alk)=CH-,*-CH2-CH2-或*-O-CH2-(*为与R1的键);Alk为低碳烷基基团;环B为可选择取代的含氮脂肪杂环基团;R1为可选择取代的含氮杂环基团,其中的氮杂环基团为从喹喔啉基,喹啉基,异喹啉基,喹唑啉基,吡嗪基,嘧啶基中选取的基团,或者与其中的5至6元脂环融合的基团;Y0为从以下(1)到(5)组成的基团:(1)可选择取代的苯基或可选择取代的芳香单环5至6元杂环基团;(2)可选择取代的氨基羰基;(3)可选择取代的氨基低碳烷基;(4)-O-R2其中R2为氢,可选择取代的低碳烷基,低环烷基,脂肪单环5至6元杂环基团,或式[AA];(5)单取代或双取代氨基;但是,当Y0为单取代或双取代氨基时,R1的含氮杂环基团不是喹喔啉基或喹啉基。
    公开号:
    WO2010030027A1
点击查看最新优质反应信息

文献信息

  • AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE
    申请人:Morimoto Hiroshi
    公开号:US20110166135A1
    公开(公告)日:2011-07-07
    The present invention provides aromatic nitrogen-containing 6-membered ring compounds having excellent PDE10 inhibitory activity. The present invention relates to an aromatic nitrogen-containing 6-membered ring compound represented by the following formula [I 0 ] or a pharmaceutically acceptable salt thereof, a method for preparing the same, and use of said compounds for PDE10 inhibitors, and a pharmaceutical composition comprising said compounds as an active ingredient: Formula [I 0 ] wherein: X 1 , X 2 and X 3 each independently are N or CH, and at least two of X 1 , X 2 and X 3 are N; A is *—CH═CH—, *—C(Alk)=CH—, *—CH 2 —CH 2 — or *—O—CH 2 — (* is a bond with R 1 ); Alk is a lower alkyl group; Ring B is an optionally substituted nitrogen-containing aliphatic heterocyclic group; R 1 is an optionally substituted nitrogen-containing heterocyclic group, a nitrogen-containing heterocyclic moiety of which is a moiety selected from the group consisting of quinoxalinyl, quinolyl, isoquinolyl, quinazolinyl, pyrazinyl, pyrimidinyl and a moiety thereof fused with a 5 to 6-membered aliphatic ring thereto; Y 0 is a group selected from the group consisting of the following (1) to (5): (1) an optionally substituted phenyl or an optionally substituted aromatic monocyclic 5 to 6-membered heterocyclic group; (2) an optionally substituted aminocarbonyl; (3) an optionally substituted amino lower alkyl; (4) —O—R 2 wherein R 2 is hydrogen, an optionally substituted lower alkyl, lower cycloalkyl, aliphatic monocyclic 5 to 6-membered heterocyclic group, or Formula [AA]; (5) mono- or di-substituted amino; provided that, when Y 0 is mono- or di-substituted amino, the nitrogen-containing heterocyclic moiety of R 1 is not quinoxalinyl or quinolyl.
    本发明提供了具有优异的PDE10抑制活性的芳香族含氮6元环化合物。本发明涉及以下式[I0]或其药学上可接受的盐,其为一种芳香族含氮6元环化合物,以及其制备方法,用于PDE10抑制剂的化合物和包含该化合物作为活性成分的药物组合物:式[I0]其中:X1、X2和X3各自独立地为N或CH,且至少两个X1、X2和X3为N;A为*—CH═CH—、*—C(Alk)=CH—、*—CH2—CH2—或*—O—CH2—(*为R1的键);Alk为低碳基;环B为可选取代的含氮脂肪族杂环基;R1为可选取代的含氮杂环基,其中含氮杂环基是从喹啉基、喹啉基、异喹啉基、喹唑啉基、吡嗪基、嘧啶基和它们与5至6元脂环环融合的基中选择的基;Y0为从以下组合中选择的基(1)到(5):(1)可选取代的苯基或可选取代的芳香单环5至6元杂环基;(2)可选取代的氨基甲酰基;(3)可选取代的氨基低碳基;(4)—O—R2,其中R2为氢、可选取代的低碳基、低环烷基、脂肪单环5至6元杂环基或式[AA];(5)单取代或双取代的氨基;但当Y0为单取代或双取代的氨基时,R1的含氮杂环基不是喹啉基或喹啉基。
  • [EN] AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS CYCLIQUES AROMATIQUES AZOTÉS À 6 CHAÎNONS ET LEUR UTILISATION
    申请人:MITSUBISHI TANABE PHARMA CORP
    公开号:WO2010030027A1
    公开(公告)日:2010-03-18
    The present invention provides aromatic nitrogen-containing 6-membered ring compounds having execellent PDE10 inhibitory activity. The present invention relates to an aromatic nitrogen-containing 6-membered ring compound represented by the following formula [I0] or a pharmaceutically acceptable salt thereof, a method for preparing the same, and use of said compounds for PDE10 inhibitors, and a pharmaceutical composition comprising said compounds as an active ingredient: Formula [I0] wherein: X1, X2 and X3 each independently are N or CH, and at least two of X1, X2 and X3 are N; A is *-CH=CH-, *-C(Alk)=CH-, *-CH2-CH2- or *-O-CH2- (* is a bond with R1); Alk is a lower alkyl group; Ring B is an optionally substituted nitrogen-containing aliphatic heterocyclic group; R1 is an optionally substituted nitrogen-containing heterocyclic group, a nitrogen-containing heterocyclic moiety of which is a moiety selected from the group consisting of quinoxalinyl, quinolyl, isoquinolyl, quinazolinyl, pyrazinyl, pyrimidinyl and a moiety thereof fused with a 5 to 6-membered aliphatic ring thereto; Y0 is a group selected from the group consisting of the following (1) to (5): (1) an optionally substituted phenyl or an optionally substituted aromatic monocyclic 5 to 6-membered heterocyclic group; (2) an optionally substituted aminocarbonyl; (3) an optionally substituted amino lower alkyl; (4) -O-R2 wherein R2 is hydrogen, an optionally substituted lower alkyl, lower cycloalkyl, aliphatic monocyclic 5 to 6-membered heterocyclic group, or Formula [AA]; (5) mono- or di-substituted amino; provided that, when Y0 is mono- or di-substituted amino, the nitrogen-containing heterocyclic moiety of R1 is not quinoxalinyl or quinolyl.
    本发明提供了具有出色的PDE10抑制活性的芳香氮含6元环化合物。本发明涉及以下式[I0]所代表的芳香氮含6元环化合物或其药学上可接受的盐,其制备方法,以及将所述化合物用作PDE10抑制剂,以及包含所述化合物作为活性成分的药物组合物:式[I0]其中:X1、X2和X3各自独立地为N或CH,并且至少两个X1、X2和X3为N;A为*-CH=CH-,*-C(Alk)=CH-,*-CH2-CH2-或*-O-CH2-(*为与R1的键);Alk为低碳烷基基团;环B为可选择取代的含氮脂肪杂环基团;R1为可选择取代的含氮杂环基团,其中的氮杂环基团为从喹喔啉基,喹啉基,异喹啉基,喹唑啉基,吡嗪基,嘧啶基中选取的基团,或者与其中的5至6元脂环融合的基团;Y0为从以下(1)到(5)组成的基团:(1)可选择取代的苯基或可选择取代的芳香单环5至6元杂环基团;(2)可选择取代的氨基羰基;(3)可选择取代的氨基低碳烷基;(4)-O-R2其中R2为氢,可选择取代的低碳烷基,低环烷基,脂肪单环5至6元杂环基团,或式[AA];(5)单取代或双取代氨基;但是,当Y0为单取代或双取代氨基时,R1的含氮杂环基团不是喹喔啉基或喹啉基。
查看更多